CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 101 enrolled
Drug / intervention
elotuzumab +3 morebiological
Likely dose
lenalidomide 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00742560
NCT00742560Phase 2Completed
CompareCT.gov

A Phase 1b/2, Multicenter, Open-label, Dose-escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed Multiple Myeloma

AbbVie (prior sponsor, Abbott)·interventional·Posted Aug 27, 2008·Updated Jan 10, 2018

In Brief

A Phase 2 clinical trial evaluating elotuzumab, lenalidomide, and 2 other interventions for Hematologic Cancer. Completed, enrolled 101 participants.

Detailed Summary

The purpose of this study is to evaluate the combination of elotuzumab, lenalidomide, and dexamethasone in subjects with relapsed multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Cancer
Countries--
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 27, 2008
Enrollment StartAug 1, 2008
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 8.2 yearsPosted 17.8 years ago

Interventions

elotuzumabbiological

Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.

lenalidomidedrug

Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle

dexamethasone oraldrug

Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)

dexamethasone injectiondrug

Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)